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Surgical Repair of Congenital Diaphragmatic Hernia During 
Extracorporeal Membrane Oxygenation: Hemorrhagic Complications 
and the Effect of Tranexamic Acid 
By F.H.J. van der Staak, A.F.J. de Haan, W.B. Geven, and C. Festen 
Nijmegen, The Netherlands 
0 Extracorporeal membrane oxygenation (ECMO) was in- 
corporated in a strategy of delayed repair of congenital 
diaphragmatic hernia (CDH) and was used for preoperative 
stabilization in patients who were unresponsive to maximal 
conventional treatment. If ECMO was required for preopera- 
tive stabilization the diaphragmatic defect was repaired 
while the patient was on ECMO. In the early experience with 
this approach all patients suffered from bleeding complica- 
tions. Therefore, we adopted the use of antifibrinolytic 
therapy with tranexamic acid (TEA) during and immediately 
after CDH repair on ECMO. The efficacy of TEA was studied in 
an unblinded study using historical controls by comparing 
the postoperative blood loss and the transfusion require- 
ments of red blood cells (RBC) in patient groups treated 
without (n = 9) and with TEA (n = IO). Patients who re- 
ceived TEA had significantly less bleeding at the surgical site 
than patients not receiving TEA (57 v 390 mL, P = .005) and 
had significantly lower RBC transfusion requirements than 
patients not receiving TEA (1.13 v2.95 mL/kg/h, P = .03). In 
the very first two patients of the TEA group we encountered 
fairly severe thrombotic complications. TEA may have con- 
tributed to those complications. Based on the authors’ 
experience they conclude: (1) TEA is effective in reducing 
postoperative blood loss, hemorrhagic complications, and 
RBC transfusion requirements associated with CDH repair 
on ECMO. (2) TEA may be responsible for thrombotic compli- 
cations. (3) The appropriate, empirically established, dosage 
and administration patterns of TEA for CDH repair during 
ECMO seem to be one bolus of 4 mg/kg TEA intravenously 
30 minutes before the anticipated CDH repair and a continu- 
ous infusion of 1 mg/kg/h TEA during the 24 hours after CDH 
repair. 
Copyright o 1997 by W.B. Saunders Company 
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S INCE EXTRACORPOREAL membrane oxygen- ation (ECMO) became available in our institution in 
January 1991, ECMO was incorporated in a protocol of 
preoperative stabilization and delayed repair for congeni- 
tal diaphragmatic hernia (CDH).’ If ECMO was neces- 
sary for preoperative stabilization, surgical repair of the 
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diaphragmatic defect was performed while the patient 
was on ECMO at the end of the ECMO-run2 
In the early experiences with this approach significant 
postoperative bleeding complications were encountered 
at the surgical site.’ In all first six patients-who form 
part of this study-bleeding complications occurred, 
requiring 455 to 1215 mL red blood cells (RBC; mean, 
850 mL). Four of the six patients were forcefully weaned 
from ECMO because of the hemorrhage, and three of 
these four died of recurrent pulmonary hypertension. 
Wilson et al3 were the first who described the effect of 
an antifibrinolytic agent on hemorrhagic complications 
during ECMO. They administered E-aminocaproic acid 
(EACA) to 42 patients who were considered to be at high 
risk for bleeding complications (such as anticipated 
surgical procedures, preexisting intracranial hemorrhage 
[ICH] or profound hypoxia), starting just before or after 
cannulation until decannulation. Compared with 68 pa- 
tients not receiving EACA, the patients who received 
EACA had significantly less bleeding while on ECMO 
and required fewer blood transfusions. This difference 
was most significant in the congenital diaphragmatic 
hernia and cardiac subgroups. The incidence of ICH in 
the neonatal subgroup was also significantly reduced in 
the EACA group. These investigators advocated the use 
of EACA for all patients who were thought to be at risk 
for hemorrhagic complications on ECMO. 
Therefore we adopted the use of an antifibrinolytic 
agent as advocated by Wilson et aL3 Since January 1993 
we administered tranexamic acid (TEA) during and after 
CDH-repair on ECMO. In this report our experience with 
hemorrhagic and thrombotic complications in CDH re- 
pair during ECMO is presented, and the effect of TEA is 
evaluated. 
MATERIALS AND METHODS 
Since January 1991, 20 high-risk CDH patients needed ECMO 
support for preoperative stabilization in our institution. In all patients 
veno-arterial ECMO was used as described by Bartlett et aL4 During the 
ECMO run heparin was titrated to maintain the activated clotting time 
(ACT) at levels of 200 to 220 seconds with ECMO-flow rates higher 
than 250 mL/min. ACTS were monitored at the bedside using the 
Hemochron (International Technidyne Cot-p, Edison, NJ). At lower 
ECMO flow rates higher ACT levels were maintained (for example, 
ACT levels of 240 to 250 seconds at ECMO flows of 50 to 200 
mL/min). ACT goals were not different in any one of the groups. 
Thrombocytes were administered to maintain their count above the 
level of 80 X 109/L pre-CDH repair and above 100 X 109/L during and 
after CDH repair. The ACT was monitored every hour, and the platelet 
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counts were determined every 8 hours. RBCs were routinely transfused 
to maintain the hematocrit greater than 40% and the hemoglobin 
concentration above 8.0 mmol/L. CDH repair was performed at the end 
of the ECMO run if the patient was weanable from ECMO and the 
ECMO flow could be decreased to 50 mL/min. 
During surgery we avoided major dissections and incidental proce- 
dures, and we used running sutures to close the defect. If the defect was 
too large for primary closure a prosthetic patch (Gore-tex soft tissue 
patch) was used. Fibrin glue was spread on the suture line at the end of 
the repair. During and directly after surgical repair we tried to preclude 
major bleeding complications by running high ECMO flows, which 
allow relatively low ACTS (aim, 180 to 200 seconds). This strategy was 
the same during the whole study period. The surgical procedure has 
been founded on a long-lasting experience, did not undergo a fundamen- 
tal change, and was performed by the most experienced surgeon in the 
first group and by several surgeons in the second group. 
Nineteen patients underwent elective repair while on ECMO; in one 
patient ECMO was stopped because of a severe intracranial hemorrhage 
at day 1 of ECMO, and she died. The patients were divided into 2 
groups. Group 1 consisted of 9 patients who underwent repair without 
the use of TEA (1991 to 1992) and group 2 contained 10 patients who 
received TEA (1993 to 1995). 
Except for the addition of TEA the ECMO protocol was identical for 
both groups. TEA administration happened in different ways. In the first 
patient TEA was given intermittently by intravenous infusion, 15 mgikg 
every 8 hours, during the first 48 postoperative hours. In all other 
patients TEA was administered by an intravenous loading bolus just 
before surgery (10 mg/kg in patients 2 and 3, and 4 mg/kg in the ensuing 
patients), followed by a continuous intravenous infusion of 2 mg/kgih 
TEA over 48 hours in the second patient and of 1 mg/kg/h TEA over 24 
hours in the third and ensuing patients. 
For all patients the total blood loss was recorded. Total blood loss was 
defined as the peroperative blood loss from the surgical site and the 
postoperative bleeding from the chest tube. The blood losses were 
calculated in reference to the body weight and the postoperative ECMO 
time (ie milliliters blood per kg of body weight and per postoperative 
ECMO hour). The transfusion requirements of red blood cells were 
assessed for the whole ECMO run as well as in relation to the weight of 
the patients, the duration of the ECMO run, and the moment of CDH 
repair. The incidence of reexploration for bleeding and the thrombotic 
complications were noted in addition to the incidence of forced 
discontinuation of ECMO because of bleeding. For statistical analysis 
of the differences in both groups the two-sided Wilcoxon’s rank sum test 
and the two-sided Fisher’s Exact test were used. P values of less than 
.05 were considered significant. 
RESULTS 
Both groups were comparable with respect to birth- 
weight, age at institution of ECMO, side of the defect, 
patch repair, and the time of CDH repair during ECMO 
(Table 1). Only for the duration of the ECMO run was 
there a significant difference between both groups. Seven 
of the nine group 1 patients (78%) and 9 of the 10 group 2 
patients (90%) had a left-sided defect. Patch repair was 
accomplished in 16 patients: 8 from group 1 (89%) and 8 
from group 2 (80%). 
Hemorrhagic complications led to a forced discontinu- 
ation of ECMO support in five of the nine patients of 
group l-in one patient even after heparinization had 
been stopped. Four of the five patients who were removed 
earlier from ECMO because of bleeding died of rebound 
pulmonary hypertension. One patient in each group 
required an abdominal reexploration because of hemor- 
rhage. There were four patients with thrombotic compli- 
cations (two in each group). The thrombotic patient 
complications consisted of an upper caval vein thrombo- 
sis centered around a central venous line placed immedi- 
ately after ECMO, at the time of decannulation, via the 
internal jugular vein. These complications seemed to be 
more severe in the first two patients of group 2. A 
chylothorax developed in both patients, which lasted for 
several weeks despite special MCT formulas and even 
complete discontinuation of enteral feeding. In one 
patient of group 1 the obstructed venous return may have 
led to a hydrocephalus. In addition, in two cases of group 
2 there were clots in the circuit. The survival rate for 
group 2 (100%) was significantly higher than for group 1 
(56%) (Fisher’s Exact test, P < .OS). 
The median total intra- and postoperative blood loss 
was significantly different: 390 mL in group 1 versus 57 
mL in group 2 (Wilcoxon’s rank sum, P = .005, Fig 1A). 
The median intra- and postoperative blood loss in refer- 
ence to the postoperative ECMO time and the body 
weight was significantly less in group 2: 2.26 ml/kg/h in 
group 1 versus 0.49 ml/kg/h in group 2 (Wilcoxon’s rank 
sum, P = .02, Fig 1B). 
The median transfusion requirement of RBC during an 
ECMO run in group 1 was significantly more than in 
group 2: 838 mL versus 442 mL (Wilcoxon’s rank sum, 
P = .003, Fig 2A). In respect to the preoperative transfu- 
sion requirement of RBC there is no difference between 
both groups: median amount of 0.83 ml/kg/h (group 1) 
versus 0.96 mL/kg/h (group 2, Wilcoxon’s rank sum, 
P = .3). The difference in intra- and postoperative require- 
ments of RBC between both groups is statistically 
significant: median of 2.96 ml/kg/h in group 1 versus 
1.13 ml/kg/h in group 2 (Wilcoxon’s rank sum, P = .03, 
Fig 2B). 
DISCUSSION 
Hemorrhage is the major complication in neonates 
during ECMO. Among all Extracorporeal Life Support 
Organization (ELSO) registry patients treated by ECMO 
hemorrhagic complications occurred in 21%.5 In CDH 
patients treated by ECMO the overall incidence of 
bleeding complications appears to be 43% (209 of 483) 
including a 24% (117 of 483) incidence of operative site 
bleeding.6 Repair of the hernia defect while on ECMO 
may increase the risk of bleeding complications up to 
58% to 60%.6.7 Our initial experience-reflected in group 
1 of this study-is consistent with these reported rates: 
six of the first 10 CDH patients treated by ECMO had 
severe hemorrhage (intracranial, 1; surgical site, 5). 
Hemorrhagic complications are a hallmark of poor out- 
come.7 A statistically significant difference in bleeding 
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Fig 1. Box-plots of intra- and postoperative blood loss after CDH 
repair on ECMO in both groups (group 1 without the use of TEA, 
group 2 with TEA). They illustrate the distribution of data. The 
bottom and the top of the box indicate the first and third quartile, the 
line in between indicates the median, and the dotted lines represent 
the extreme values (range). (A) Total volume (mL) and (6) volume per 
kg body weight per postoperative ECMO time (mL/kg/hi. 
complications has been found between surviving and 
nonsurviving CDH patients who needed ECMO sup- 
port.6,7 The reported incidence of fatal hemorrhage is 4% 
to 5%.@ However, this rate is probably higher because 
any hemorrhagic complication may force the patient to be 
removed from ECMO earlier, and the immediate cause of 
death would be classified as pulmonary failure rather than 
hemorrhagic.6 We only can confirm this experience 
because all patients who died in this series had major 
hemorrhagic complications. 
So far we repair CDH on ECMO late in the ECMO 
course when the patient had been shown to be weanable 
from ECMO. In this concept, a recurrence of persistent 
pulmonary hypertension of the newborn (PPHN), elicited 
by the surgical procedure and the consequently dimin- 
ished thoracic compliance, can be controlled by ECMO, 
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Fig 2. Box-plots of transfusion requirements of RBCs in CDH 
patients, treated without (group 1) and with TEA (group 2). They 
illustrate the distribution of data. The bottom and the top of the box 
indicate the first and third quartile, the line in between indicates the 
median and the dotted lines represent the extreme values (range). (A) 
Total volume during the whole ECMO run. IB) Volume per kg body 
weight per postoperative ECMO hour (mL/kg/h). 
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Table 1. Demographic Data 
Group 1 Group 2 
(n = 9) (n = 10) 
Birth weight(g) 3,200 3,050 
(2,880, 3,660) (2,700, 4,050) 
Age at ECMO (h) 25 18 
(18, 27) (16, 28) 
Duration of ECMO (h) 181 130 
(150,217) (I 10, 167) 
Time of CDH repair (ECMO h) 108 92 
(87, 143) (67, 1101 
NOTE. The median values are stated with the 25% and 75% percentiles for all variables. 
Wilcoxon’s Rank Sum 
P 
.96 
.68 
.02 
.15 
whereas ECMo could be withdrawn soon in case of 
hemorrhagic complications. 
Adhering to our strategy, iri which the benefits of 
perioperative ECMO support have to be outweighed by 
the risks of hemorrhagic complications, it seemed to be 
important to diminish the chance of those complications. 
Initially it was thought that bleeding complications 
during ECMO were caused by the anticoagulation. Un- 
doubtedly heparinization is an impoitant, but certainly 
not the only, factor in the occurrence of hemorrhage. It is 
known from the cardiopulm&uy bypass (CPB) surgery, 
that fibrinolysis is a cause of postop&ative bleeding and 
that the fibrinolytic activity increased immediately after 
CPB had begun and remained elevated throughout the 
period of extracorporeal circul&ion (ECC).9 so, the 
increased fibrinolytic activity see&s to be caused by ECC 
itself.9 Fibrinolysis is believed to play a role in the 
increased hemorrhagic tendency in patients who require 
extiacorporeal life support (ECLS) as well.‘Ov” 
The increased fibrinolysis during ECC and ECLS is 
possibly caused by an imbalance between tissue plasmino- 
gen activator (TPA) and plasminogen activator inhibitor 
(PAI), two of the major componerits regulating fibrinoly- 
sis” (Fig 3). McVeen eJ allo found a marked elevation of 
both PA1 activity and TPA antigen in pre-ECMO infants 
experiencing respiratory distress. After institution of 
ECLS there is a rapid reduction of PA1 activity within 24 
hours, whereas TPA levels appear to remain more ele- 
Fibrinogm 
Fibrin 
Fig 3. Schematic diagram of the fibrinolytic system. EACA and 
TEA inhibit fibrinolysis by b/nding to plasminogen and plasmin. 
Urokinase and TPA accelerate the formation of plasmin from plasmino- 
gen. 
vated and decline more gradually during ECMO treat- 
ment.lO This imbalance may cause an increased risk for 
hemorrhage. Therefore, antifibrinolytic therapy repre- 
sents a pharmacological modality to reduce hemorrhagic 
complications on ECMO. 
Drugs used to inhibit fibrinolysis during and after CPB 
surgery are epsilon-aminocaproic acid (EACA), TEA and 
aprotinine.12s13 EACA and TEA inhibit fibrinolysis by 
binding to the iysine binding sites of plasminogen and 
plasmin, which are the binding sites for fibrin (Fig 3). In 
this manner they blocked the fibrin breakdown by 
plasmin. The affinity of TEA for plasminogen is much 
stronger than EACA, so that TEA is 6 to 10 times as 
potent as EACA.‘” Moreover TEA also competitively 
inhibits the activation of enterokinase. EACA has been 
adopted for use in neonatal ECLS patients by Wilson et 
al3 Because EACA was not registered in the Netherlands, 
we choose TEA instead of EACA. Because the optimal 
dosage of TEA for neonates on ECMO is not known, we 
tried to determine the dosage and the means of adminis- 
tration on the basis of the report of Horrow et alI3 about 
TEA. The recqmmended dosage by the manufacturer and 
the dosage of EACA used by Wilson (taking into 
consideration the greater efficacy of TEA) gave us 
guidelines for the dosing scheme.3a’3 
Patients who received TEA perioperatively had signifi- 
cantly less blood loss while on ECMO than the patierits 
who did not receive TEA (Wilcoxon’s rank sum, 
P = .005). Similarly the transfusion requiiements of 
RBC were significantly less in the TEA-treated group 
(Wilcoxon’s rank sum, P = .003). No patients in the 
TEA-treated group had to be withdrawn early from 
ECMO support because of major bleeding. The survival 
rate for group 2 was much higher (100% v 56%). The 
improved survival in group 2 may be attributed to the 
decreased occurrence of severe hemorrhages. 
Those data may reflect the possibility that antifibrino- 
lytic therapy has played a role in the diminution of 
bleeding complications and the improved survival. How- 
ever, these results may be attributed as well to the 
increased experience of the whole ECMO team. Because 
this is an unblinded study with historical controls, it is 
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more difficult to unravel the influence of the gained 
experience on the one hand and the influence of TEA on 
the other hand on the improved results. It can be supposed 
that less blood loss and less RBC requirement can be 
explained by a better and more well-balanced anticoagu- 
lation management in the second group as a result of 
learning over time. 
significantly from the requirements in the second period 
(group 2 with the use of TEA, 1.13 n&/kg/h) (P = .03). 
(4) The surgical procedure was well established over 
years and did not change with the introduction of ECMO 
or during the study period. Therefore it may be concluded 
that TEA is effective in controlling bleeding complica- 
tions and in reducing RBC transfusion requirements. 
To investigate the effect of the learning curve, the RBC 
requirements were studied in all other ECMO patients 
(CDH excepted) in the same time frames as group 1 and 2 
CDH patients were treated. In the first episode (1991 to 
1992) the median RBC requirement during ECMO was 
0.66 ml/kg/h of ECMO versus 0.75 ml/kg/h in the 
second episode (1993 to 1995, P = 0.27). This observa- 
tion does not suggest a big alteration in ECMO handling 
caused by the learning curve. 
With respect to the operative technique there was no 
fundamental change in the surgical approach with the 
advent of ECMO. This technique has been rooted in a 
more than 20-year surgical experience with CDH repair. 
So it is hard to believe that a learnirig curve or a big 
alteration in the operative procedure is responsible for the 
bleeding complications in the early part of this study 
(group 1 CDH patients). 
Although the validity of this study may be a point of 
debate because of the use of historical controls, the 
following points can be made: (1) The preoperative RBC 
requirements in CDH patients on ECMO in both episodes 
(0.83 ml/kg/h in group 1 and 0.96 ml/kg/h in group 2) 
were comparable to the RBC requirements in all other 
indications in both episodes (0.66 ml/kg/h and 0.75 
@/kg/h, respectively). (2) The postoperative RBC re- 
quirements after CDH repair on ECMO in the second 
episode (group 2, 1.13 ml/kg/h) were comparable to the 
RBC requirements in the pre-CDH repair episodes (0.83 
to 0.96 ml/kg/h) and in all other ECMO indications (0.66 
to 0.75 ml/kg/h). (3) The postoperative RBC require- 
ments after CDH repair on ECMO in the first period 
(group 1 without the use of TEA, 2.96 ml/kg/h) differed 
Although thrombotic complications are to be expected 
with the use of TEA, the reports concerning antifibrino- 
lytic therapy during and after CPB surgery did not show 
an increase in those complications.‘2J3 In this study 
rather severe thrombotic complications were encountered 
in the first two patients treated with TEA. Right atria1 and 
superior caval vein (SCV) thrombosis developed with an 
SCV syndrome and a long-lasting chylothorax. It was 
unclear whether these complications of central venous 
line thrombosis several days after ECMO were caused by 
TEA because we experienced the similar complications 
previously in two patients of group 1 who did not receive 
TEA. In addition those complications have been reported 
as well after ECMO without the use of antifibrinolytic 
therapy, I491 5and thrombosis around an indwelling central 
venous line is a fairly known complication in neonates.16 
However, meeting these problems and noting fatal throm- 
botic complications by the use of antifibrinolytic therapy,17 
we decided to adapt the dosage and the administrition of 
TEA. Since that alteration, neither severe hemorrhages 
nor severe thrombotic complications were observed. 
This study demonstrates that TEA is effective in 
reducing postoperative blood loss and hemorrhagic com- 
plications associated with CDH repair on ECMO. It also 
reflects the possibility that TEA may be responsible for 
severe thrombotic complications. Empirically, based on 
our experience, the appropriate dosage and administra- 
tion pattern of TEA for CDH repair during ECMO seem 
to be one bolus of 4 mg/kg TEA intravenously 30 minutes 
before the anticipated CDH repair and a continuous 
infusion of 1 mg/kg/h TEA during the 24 hours after 
CDH repair. 
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